Evidence map›Paper›PMID 41151860›Full record

ArticleCancer genomics & proteomics

Expression of Glucocorticoid Receptor and FOXO1/phospho-FOXO1 in Bladder Cancer as Independent Prognosticators.

Hiroki Ide, Mohammad Amin Elahi Najafi, Takuo Matsukawa, Tomoyuki Tatenuma, Mototsugu Oya, Hiroshi Miyamoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hiroki IdeDepartments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.
Mohammad Amin Elahi NajafiDepartment of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, U.S.A.
Takuo MatsukawaDepartment of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, U.S.A.
Tomoyuki TatenumaDepartment of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, U.S.A.
Mototsugu OyaDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.
Hiroshi MiyamotoDepartments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.; hiroshi_miyamoto@urmc.rochester.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimCross-talk between forkhead box O1 (FOXO1), a transcriptional factor known to function as a tumor suppressor MATERIALS AND

methodsImmunohistochemical staining for GR, FOXO1, and p-FOXO1 (a phosphorylated/inactivated form) was performed in a set of bladder cancer tissue microarray comprising 50 low-grade non-invasive tumors, 28 high-grade non-muscle-invasive tumors, and 51 high-grade muscle-invasive tumors. Western blotting for FOXO1 and p-FOXO1 was also conducted in human bladder cancer cells.

resultsGR expression was detected in 109 [84.5%; 39 (30.2%) weakly positive (1+), 39 (30.2%) moderately positive (2+), 31 (24.0%) strongly positive (3+)] tumors, whereas FOXO1 and p-FOXO1 were immunoreactive in 17 [13.2%; 16 (12.4%) 1+, 1 (0.8%) 2+] and 71 [55.0%; 57 (44.2%) 1+, 14 (10.9%) 2+] tumors, respectively. The expression levels of GR were positively and negatively correlated with those of FOXO1 (

conclusionThe expression levels of GR and FOXO1 or p-FOXO1 were strongly correlated in bladder cancer. Specific GR/FOXO1 and GR/p-FOXO1 expression profiles served as independent predictors of disease recurrence or progression.

Indexed as

Biomarkers, TumorForkhead Box Protein O1Receptors, GlucocorticoidUrinary Bladder NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPhosphorylationPrognosisBiomarkers, TumorForkhead Box Protein O1FOXO1 protein, humanReceptors, GlucocorticoidBladder cancerFOXO1glucocorticoid receptorimmunohistochemistryphospho-FOXO1

Identifiers

PMID41151860
PMCPMC12577604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.